Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab as First-line Treatment for dMMR/MSI Non-colorectal/Non-endometrial Advanced Cancers
NCT06333314Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Jul 2024
- Primary completion
- Oct 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC), ampulla of Vater carcinoma (AVC), adrenocortical carcinoma (ACC) and 5 more comparing Dostarlimab with Standard of care (2 arms). Primary endpoint: Progression-free survival up to 3 years. Started Jul 2024; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
pancreatic adenocarcinoma (PDAC)ampulla of Vater carcinoma (AVC)adrenocortical carcinoma (ACC)neuroendocrine carcinoma (NEC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06333314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333314.